ES2280136B1 - Asociacion a dosis fija de fitato y zinc. - Google Patents

Asociacion a dosis fija de fitato y zinc. Download PDF

Info

Publication number
ES2280136B1
ES2280136B1 ES200600377A ES200600377A ES2280136B1 ES 2280136 B1 ES2280136 B1 ES 2280136B1 ES 200600377 A ES200600377 A ES 200600377A ES 200600377 A ES200600377 A ES 200600377A ES 2280136 B1 ES2280136 B1 ES 2280136B1
Authority
ES
Spain
Prior art keywords
phytate
association
zinc
hydroxyapatite
crystallization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200600377A
Other languages
English (en)
Spanish (es)
Other versions
ES2280136A1 (es
Inventor
Felix Grases Freixedas
Joan Perello Bestard
Bernat Isern Amengual
Pilar Sanchis Cortes
Rafael M. Prieto Almirall
Bauza Costa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitat de les Illes Balears
Original Assignee
Universitat de les Illes Balears
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200600377A priority Critical patent/ES2280136B1/es
Application filed by Universitat de les Illes Balears filed Critical Universitat de les Illes Balears
Priority to JP2008554771A priority patent/JP5554499B2/ja
Priority to AU2007216453A priority patent/AU2007216453B2/en
Priority to SI200730738T priority patent/SI1984001T1/sl
Priority to CA2641216A priority patent/CA2641216C/en
Priority to RU2008138358/15A priority patent/RU2415673C2/ru
Priority to MX2008010502A priority patent/MX2008010502A/es
Priority to BRPI0707008-0A priority patent/BRPI0707008A2/pt
Priority to PL07726369T priority patent/PL1984001T3/pl
Priority to AT07726369T priority patent/ATE516035T1/de
Priority to DK07726369.7T priority patent/DK1984001T3/da
Priority to PT07726369T priority patent/PT1984001E/pt
Priority to CN200780005915XA priority patent/CN101384266B/zh
Priority to EP07726369A priority patent/EP1984001B1/en
Priority to PCT/EP2007/051413 priority patent/WO2007093611A1/en
Priority to US12/279,616 priority patent/US8377908B2/en
Publication of ES2280136A1 publication Critical patent/ES2280136A1/es
Application granted granted Critical
Publication of ES2280136B1 publication Critical patent/ES2280136B1/es
Priority to NO20083901A priority patent/NO341286B1/no
Priority to CY20111100955T priority patent/CY1111913T1/el
Priority to US13/770,782 priority patent/US9144578B2/en
Priority to JP2014023681A priority patent/JP5908933B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Catalysts (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Dental Preparations (AREA)
ES200600377A 2006-02-17 2006-02-17 Asociacion a dosis fija de fitato y zinc. Expired - Fee Related ES2280136B1 (es)

Priority Applications (20)

Application Number Priority Date Filing Date Title
ES200600377A ES2280136B1 (es) 2006-02-17 2006-02-17 Asociacion a dosis fija de fitato y zinc.
PT07726369T PT1984001E (pt) 2006-02-17 2007-02-14 Associação de fitato e zinco numa dose fixa
SI200730738T SI1984001T1 (sl) 2006-02-17 2007-02-14 Zveza fiksnega odmerka fitata in cinka
CA2641216A CA2641216C (en) 2006-02-17 2007-02-14 Fixed-dose association of phytate and zinc
RU2008138358/15A RU2415673C2 (ru) 2006-02-17 2007-02-14 Композиция с фиксированной дозой фитата и цинка
MX2008010502A MX2008010502A (es) 2006-02-17 2007-02-14 Asociacion de fitato y zinc de dosis baja.
AU2007216453A AU2007216453B2 (en) 2006-02-17 2007-02-14 Fixed-dose association of phytate and zinc
PL07726369T PL1984001T3 (pl) 2006-02-17 2007-02-14 Połączenie ustalonych dawek fitynianu i cynku
AT07726369T ATE516035T1 (de) 2006-02-17 2007-02-14 Fixdosisassoziation von phytat und zink
DK07726369.7T DK1984001T3 (da) 2006-02-17 2007-02-14 Fikseret dosisassociation af phytat og zink
JP2008554771A JP5554499B2 (ja) 2006-02-17 2007-02-14 フィチン酸塩と亜鉛の一定量組み合わせ
BRPI0707008-0A BRPI0707008A2 (pt) 2006-02-17 2007-02-14 associação em doses fixas de fitato e zinco
CN200780005915XA CN101384266B (zh) 2006-02-17 2007-02-14 肌醇六磷酸和锌的固定剂量结合物
PCT/EP2007/051413 WO2007093611A1 (en) 2006-02-17 2007-02-14 Fixed-dose association of phytate and zinc
US12/279,616 US8377908B2 (en) 2006-02-17 2007-02-14 Fixed-dose association of phytate and zinc
EP07726369A EP1984001B1 (en) 2006-02-17 2007-02-14 Fixed-dose association of phytate and zinc
NO20083901A NO341286B1 (no) 2006-02-17 2008-09-11 Fiksert-dose-assosiasjon av fytat og sink
CY20111100955T CY1111913T1 (el) 2006-02-17 2011-10-06 Συνδυασμος σταθερης δοσης φυτικου αλατος και ψευδαργυρου
US13/770,782 US9144578B2 (en) 2006-02-17 2013-02-19 Fixed-dose association of phytate and zinc
JP2014023681A JP5908933B2 (ja) 2006-02-17 2014-02-10 フィチン酸塩と亜鉛の一定量組み合わせ

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200600377A ES2280136B1 (es) 2006-02-17 2006-02-17 Asociacion a dosis fija de fitato y zinc.

Publications (2)

Publication Number Publication Date
ES2280136A1 ES2280136A1 (es) 2007-09-01
ES2280136B1 true ES2280136B1 (es) 2008-08-16

Family

ID=38007006

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200600377A Expired - Fee Related ES2280136B1 (es) 2006-02-17 2006-02-17 Asociacion a dosis fija de fitato y zinc.

Country Status (18)

Country Link
US (2) US8377908B2 (https=)
EP (1) EP1984001B1 (https=)
JP (2) JP5554499B2 (https=)
CN (1) CN101384266B (https=)
AT (1) ATE516035T1 (https=)
AU (1) AU2007216453B2 (https=)
BR (1) BRPI0707008A2 (https=)
CA (1) CA2641216C (https=)
CY (1) CY1111913T1 (https=)
DK (1) DK1984001T3 (https=)
ES (1) ES2280136B1 (https=)
MX (1) MX2008010502A (https=)
NO (1) NO341286B1 (https=)
PL (1) PL1984001T3 (https=)
PT (1) PT1984001E (https=)
RU (1) RU2415673C2 (https=)
SI (1) SI1984001T1 (https=)
WO (1) WO2007093611A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2280136B1 (es) * 2006-02-17 2008-08-16 Universitat De Les Illes Balears Asociacion a dosis fija de fitato y zinc.
MX339909B (es) * 2011-07-12 2016-06-14 Procter & Gamble Composiciones para el cuidado bucal que comprende acido fitico.
ES2486441B1 (es) * 2014-04-02 2015-06-11 Universitat De Les Illes Balears Preparaciones combinadas de acidificantes urinarios e inhibidores de la cristalización y su aplicación para el tratamiento o prevención de la litiasis renal fosfática o inducida por fosfato cálcico
CN107106423A (zh) * 2014-12-26 2017-08-29 高露洁-棕榄公司 用于口腔护理的磷酸锌络合物
DE102016013737A1 (de) 2016-11-17 2018-05-17 WindplusSonne GmbH Hexahydroxycyclohexanhexaphosphorsäureestersalze zur Behandlung von Kalzinose sowie diätische Lebensmittel mit Hexahydroxycyclohexanhexaphosphorsäureestersalzen als Zusatzstoffe
CN108444985B (zh) * 2018-04-25 2021-02-02 山西省食品药品检验所(山西省药品包装材料监测中心) 一种肾精子icp-ms鉴别方法及应用
CA3111331A1 (en) * 2018-09-18 2020-03-26 Inositec Ag Calcium oxalate crystallization inhibitors for renal disorders
US11633416B1 (en) 2020-03-06 2023-04-25 Arcus Biosciences, Inc. Oral formulations of CD73 compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2007238A6 (es) * 1988-06-17 1989-06-01 Univ Illes Balears Procedimiento para la preparacion de fitato-zn (ii)>
CN1102978A (zh) * 1993-11-23 1995-05-31 姚焕新 多功能牙膏
JPH08104635A (ja) * 1994-10-06 1996-04-23 Ichimaru Pharcos Co Ltd フィチン酸亜鉛を有効成分とする外用製剤

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3934001A (en) 1965-12-07 1976-01-20 Lever Brothers Company Oral compositions containing germicidally active plastic powders
NL149701C (nl) 1965-12-08 1981-05-15 Procter & Gamble Werkwijze voor het bereiden van een tegen tandsteen werkzaam tandverzorgingsmiddel, dat als werkzaam bestanddeel een fosfonzuurderivaat bevat, alsmede gevormd tandverzorgingsmiddel.
US3934002A (en) 1972-06-30 1976-01-20 The Procter & Gamble Company Oral compositions for plaque, caries and calculus retardation with reduced staining tendencies
US4215105A (en) 1978-10-27 1980-07-29 Colgate-Palmolive Company Anticalculus oral composition
JPS5835965B2 (ja) 1979-07-31 1983-08-05 ライオン株式会社 口腔用組成物
JPS5846483B2 (ja) 1979-09-20 1983-10-17 ライオン株式会社 口腔用組成物
JPS6043322B2 (ja) * 1979-09-05 1985-09-27 ライオン株式会社 口腔用組成物
US4515772A (en) 1982-06-22 1985-05-07 The Procter & Gamble Company Oral compositions
US4808409A (en) 1984-08-16 1989-02-28 Board Of Trustees, University Of Illinois Low cariogenic sweetening agents
JPS6229526A (ja) * 1985-08-01 1987-02-07 Wakamoto Pharmaceut Co Ltd 高カルシウム尿症の治療及び予防剤
US4627977A (en) 1985-09-13 1986-12-09 Colgate-Palmolive Company Anticalculus oral composition
US4808401A (en) 1985-09-13 1989-02-28 Colgate-Palmolive Company Anticalculus oral composition
JPH0729909B2 (ja) * 1986-11-28 1995-04-05 ライオン株式会社 口腔用組成物
JPH01305033A (ja) * 1988-06-01 1989-12-08 Sanwa Kagaku Kenkyusho Co Ltd 循環改善剤及び循環改善機能性食品並びにし好品
US5300289A (en) * 1991-12-10 1994-04-05 The Dow Chemical Company Phytate antimicrobial compositions in oral care products
US5286479A (en) * 1991-12-10 1994-02-15 The Dow Chemical Company Oral compositions for suppressing mouth odors
JPH10182383A (ja) * 1996-12-24 1998-07-07 Lion Corp 口腔用組成物
IT1306133B1 (it) * 1999-04-22 2001-05-30 Sigma Tau Healthscience Spa Composizione comprendente una carnitina ed un inositolfosfato, utilequale integratore dietetico o medicamento.
JP2004065249A (ja) * 2002-06-13 2004-03-04 Fumio Hara フィチン酸、イノシトールおよびナイアシンの富化方法、食品の製造方法、並びに食品
ES2232302B1 (es) * 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
CN1259033C (zh) * 2004-06-24 2006-06-14 江西航天日用化工发展有限责任公司 可去除烟黄斑牙垢的复方牙膏及其制备方法
WO2007063507A2 (en) * 2005-11-29 2007-06-07 The Procter & Gamble Company Dentifrice composition comprising binder system comprising hydrophilic clay material
EP1962787A2 (en) * 2005-12-20 2008-09-03 The Procter and Gamble Company Oral care compositions comprising zinc and phytate
ES2280136B1 (es) * 2006-02-17 2008-08-16 Universitat De Les Illes Balears Asociacion a dosis fija de fitato y zinc.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2007238A6 (es) * 1988-06-17 1989-06-01 Univ Illes Balears Procedimiento para la preparacion de fitato-zn (ii)>
CN1102978A (zh) * 1993-11-23 1995-05-31 姚焕新 多功能牙膏
JPH08104635A (ja) * 1994-10-06 1996-04-23 Ichimaru Pharcos Co Ltd フィチン酸亜鉛を有効成分とする外用製剤

Also Published As

Publication number Publication date
RU2008138358A (ru) 2010-03-27
WO2007093611A1 (en) 2007-08-23
CA2641216A1 (en) 2007-08-23
JP2014139182A (ja) 2014-07-31
CN101384266A (zh) 2009-03-11
JP5908933B2 (ja) 2016-04-26
RU2415673C2 (ru) 2011-04-10
JP2009526818A (ja) 2009-07-23
BRPI0707008A2 (pt) 2011-04-12
CY1111913T1 (el) 2015-11-04
CN101384266B (zh) 2013-03-20
ATE516035T1 (de) 2011-07-15
PT1984001E (pt) 2011-10-18
JP5554499B2 (ja) 2014-07-23
NO20083901L (no) 2008-09-11
US8377908B2 (en) 2013-02-19
PL1984001T3 (pl) 2012-02-29
EP1984001B1 (en) 2011-07-13
EP1984001A1 (en) 2008-10-29
US9144578B2 (en) 2015-09-29
MX2008010502A (es) 2008-10-23
DK1984001T3 (da) 2011-11-07
SI1984001T1 (sl) 2011-12-30
CA2641216C (en) 2014-04-15
AU2007216453A1 (en) 2007-08-23
NO341286B1 (no) 2017-10-02
AU2007216453B2 (en) 2012-09-27
US20140056994A1 (en) 2014-02-27
ES2280136A1 (es) 2007-09-01
US20090035232A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
US9144578B2 (en) Fixed-dose association of phytate and zinc
ES2922501T3 (es) Uso de sulfatos de colesterol oxigenados (OCS) para el tratamiento de disfunción renal
WO2007138147A1 (es) Utilización de fitato como agente inhibidor de la disolución de cristales de sales cálcicas para la prevención de la osteoporosis
ES2776402T3 (es) Composición que contiene ácido fítico, magnesio y polifenoles para el tratamiento o la prevención de la litiasis renal
CA2788865A1 (en) Composition comprising as active ingredient l-carnitine in combination with hydroxykynurenine-0-beta-dl-glucoside, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation
AU2019354855B2 (en) Silicic acids for use in the treatment of periodontitis
ES2232302A1 (es) Myo-inositol hexafosfato para uso topico.
CA3070659A1 (en) Composition for use in the prevention and treatment of pathologies of the cardiovascular apparatus
ES2842624T3 (es) El pirofosfato oral para su uso en la reducción de la calcificación de tejidos
ES2773628T3 (es) Combinación de un acidificante urinario y un inhibidor de la cristalización del fosfato cálcico para el tratamiento o prevención de la litiasis renal
EP2180895A1 (en) Methods for improving healing of an oral lesion using a glycerophosphate salt
RU2497527C2 (ru) Фармацевтическая композиция для лечения расстройств, включающих раздражение желудочно-кишечного тракта
JP7096069B2 (ja) 骨再生剤
ES2339265T3 (es) Uso de acetil l-carnitina en combinacion con propionil l-carnitina y sildenafil para el tratamiento de la difuncion erectil.
Naji Materials Used in Remineralization of Initial Caries
CN105250332B (zh) 一种护龈固齿多效口腔治疗物及其应用
RU2380081C2 (ru) Состав для лечения и профилактики заболеваний полости рта
Lander A Nutrient/Toxin Interaction Theory of the Etiology and Pathogenesis of Chronic Pain-Fatigue Syndromes: Part I
KR20060023503A (ko) 심장 및 혈관질환, 혈액의 산성화의 예방 또는 치료를위한 조성물
JP2001500161A (ja) カルシウム、ビタミンｄ及びアミノ酸を含有し、骨粗鬆症の処置のための、そして破損骨治療を促進するための組成物
WO2012082014A2 (ru) Фармацевтическая композиция «мицефосфон», стимулирующая регенерацию опорных тканей

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20070901

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2280136B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20260226